Management ChangeJun 2, 2026, 06:36 AM
CASI Pharmaceuticals Director Dr. Barbara Krebs-Pohl Resigns
AI Summary
CASI Pharmaceuticals, Inc. announced that Dr. Barbara Krebs-Pohl, PhD, has resigned from her position as a director of the Company, effective May 31, 2026. The Company stated that her resignation was not due to any disagreement. Dr. Krebs-Pohl has agreed to continue serving the Company as an independent consultant under mutually agreed terms.
Key Highlights
- Dr. Barbara Krebs-Pohl resigned as a director of CASI Pharmaceuticals.
- Her resignation was effective May 31, 2026.
- The Company stated her departure was not due to any disagreement.
- Dr. Krebs-Pohl agreed to serve as an independent consultant.
Price Impact